Biomarkers that reliably identify or even predict disease manifestations in systemic lupus erythematosus (SLE) are needed. In a recent issue of the Clinical Journal of the American Society of ...
Lupus puts the body at war with itself. In patients with the most common form, systemic lupus erythematosus ... patients are rarely checked frequently for kidney disease. The two surveys also ...
The Lupus Foundation of America, North Carolina Chapter is dedicated to improving the quality of life for all people affected by Lupus through programs of research ...
Systemic lupus erythematosus is a complex autoimmune disorder affecting multiple organ systems. Glomerulonephritis ... Conventional lupus nephritis (LN) treatment based on cyclophosphamide ...
In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess therapies for initial management of lupus nephritis (LN), focusing on their ...
Felzartamab is under clinical development by Biogen and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...
Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...
Belimumab is under clinical development by GSK and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 63% phase transition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback